Iambic's $175M IPO signals new biotech funding rules. Learn what makes AI drug discovery attractive and what future startups need to succeed.
·
·
7 min read
Iambic's $2.5B IPO signals a new biotech era. Learn what drives premium valuations now, distinguishing true innovation from speculation.
·
·
7 min read
Iambic's 2026 IPO shows biotech's market challenges. Learn how companies like Iambic overcome investor skepticism and regulatory hurdles.
·
·
6 min read
Why 10-year Treasury yields above 4.5% mean less cheap capital for startups. Learn what founders must do to survive and attract investors.
·
·
8 min read
Construction tech VC funding dropped 30% in 2025. Learn why and how startups must adapt funding strategies for a cautious market.
·
·
6 min read
Bitcoin's volatility poses major liquidity risks for startups in 2026. See why fluctuating crypto impacts financial stability and fundraising.
·
·
3 min read
AgriGen bets $4.5B on CRISPR soybeans by 2026. See why gene editing is key for resilient crops and how AgriGen plans to stay ahead.
·
·
9 min read
AI biotech funding hit $3.5 billion for crops in 2025. See how AI speeds up gene editing for maize and what it means for food security.
·
·
8 min read
AbbVie commits $1.2B to Iambic's AI platform for faster drug discovery. See how AI speeds up identifying new therapies, reducing time and cost.
·
·
7 min read
Maize yield losses hit 40%. See how agritech startups, with $4.2B funding in 2025, accelerate disease resistance and what challenges remain.
·
·
6 min read